AstraZeneca entered the next-gen obesity race late and is moving through Phase 2b with a multi-asset strategy. The February 2026 $1.2 billion CSPC Pharmaceuticals collaboration brought in the two molecules that anchor the ASCEND program: AZD9550 (GLP-1 + glucagon dual agonist) and AZD6234 (selective amylin analog). Combined as a two-molecule fixed-dose combination, ASCEND is positioned as a 'triple mechanism' targeting fat-selective weight loss and organ protection — the safety-and-organ-protection lane that competitors leave open.
The broader obesity portfolio also includes eleglipron (formerly elecoglipron / AZD5004 / ECC5004), the oral small-molecule GLP-1 licensed from Eccogene that met primary endpoints in two Phase 2b trials — VISTA in 310 obesity patients (26-week weight loss) and SOLSTICE in 406 type-2 diabetes patients (26-week HbA1c versus semaglutide). AstraZeneca held back exact weight-loss numbers at the April 29 Q1 print, framing the molecule as 'very competitive,' with full data scheduled for ADA 2026 in June and a comprehensive Phase 3 program now committed. Macrocyclic peptide platform deals — including the early-2025 Syneron Bio collaboration worth up to $3.4 billion in milestones — extend the company's peptide-discovery footprint.
Stories here cover trial readouts, partnership economics, and the broader late-mover obesity strategy. See #azd9550, #azd6234, and #ascend.
BioSpace's reaction to AstraZeneca's elecoglipron VISTA Phase 2b readout (10.5% weight loss at 26 weeks) framed it as 'relatively underwhelming' next to Structure Therapeutics' aleniglipron (up to 16.3% at 44 weeks, Nature Medicine publication on Friday). Both are oral small-molecule GLP-1s with Phase 3 plans for the second half of 2026, but elecoglipron's lower number gives Structure a clearer differentiation story heading into its Phase 3 start. AstraZeneca will lean on its combination strategy with dapagliflozin and AZD0780 to position elecoglipron.
AstraZeneca presented VISTA Phase 2b data at ADA 2026 with simultaneous Lancet publication. In adults with obesity or overweight plus comorbidity, oral elecoglipron 75 mg produced 10.5% mean weight loss at 26 weeks versus 0.6% on placebo, continuing to 11.8% by 36 weeks, alongside blood-pressure and inflammation reductions. The companion SOLSTICE T2D trial showed 1.9-point HbA1c reductions with 90% reaching HbA1c under 7% and 7.7% weight loss. AstraZeneca announced an extensive Phase 3 program covering obesity, T2D, and cardiovascular and kidney outcome trials.
Eccogene and AstraZeneca presented a Sunday June 7 poster on the safety, tolerability, and PK/PD of elecoglipron (AZD5004/ECC5004) in Chinese adults with obesity or overweight, with or without type 2 diabetes. The Monday June 8 symposium covers the VISTA Phase 2b obesity readout and the SOLSTICE Phase 2b trial in type 2 diabetes, where the oral GLP-1 reduced HbA1c at 26 weeks and supported a Phase 3 transition. AstraZeneca plans to develop elecoglipron as an oral combination backbone alongside dapagliflozin in diabetes/CKD/HF and AZD0780 in dyslipidemia.
Eccogene and AstraZeneca will present multiple datasets for the oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004/ECC5004) at ADA 2026 on June 7-8, including a late-breaking Phase 1b study conducted in China, plus the Phase 2b VISTA trial in obesity (which met its primary endpoints) and the SOLSTICE Phase 2b trial in type 2 diabetes. The slate deepens the oral-GLP-1 contest forming below Lilly's orforglipron.
Syneron Bio, a Beijing-based macrocyclic peptide drug discovery company, closed a $150 million Series B led by an international life-science fund with co-leads Decheng Capital and CDH VGC, roughly four months after a $100 million Series A. Investors include a subsidiary of the Abu Dhabi Investment Authority, Qiming Venture Partners, and existing shareholder AstraZeneca, whose 2025 platform partnership carried $75 million upfront and near-term payments plus up to $3.4 billion in milestones. The raise reflects continued investor appetite for macrocyclic and oral peptide platforms, alongside Pinnacle Medicines' $89 million round.
AstraZeneca's eleglipron (formerly elecoglipron / AZD5004 / ECC5004), the oral small-molecule GLP-1 agonist licensed from Eccogene in 2023, met primary endpoints in two Phase 2b trials with results detailed at the company's April 29 Q1 print: VISTA (NCT06579092, 310 obesity patients, 26-week weight loss) and SOLSTICE (NCT06579105, 406 type-2 diabetes patients, 26-week HbA1c change vs semaglutide and placebo). AstraZeneca held back exact weight-loss numbers, framing the molecule as 'very competitive,' with full data scheduled for the American Diabetes Association meeting in June. The company committed to a comprehensive Phase 3 program targeting both weight-loss efficacy and outcome benefits, with monotherapy and fixed-dose combination programs anchored against the SYH2082 dual-agonist and LiquidGel monthly-dosing platform from the $18.5B CSPC Pharmaceuticals collaboration.
AstraZeneca's ASCEND program is active in Phase 2b, combining AZD9550 (GLP-1 + glucagon dual agonist) with AZD6234 (selective amylin analog) in a two-molecule triple-mechanism strategy aimed at fat-selective weight loss and organ protection. Individual assets are also in Phase 2. The combination reflects the February 2026 $1.2 billion CSPC Pharmaceuticals collaboration that brought both molecules into AstraZeneca's portfolio, alongside elecoglipron (AZD5004 / ECC5004), the small-molecule oral GLP-1 that posted 5.8% weight loss over four weeks in Phase 1b in China. AstraZeneca enters the next-gen obesity race later than Lilly, Novo, Roche, and Boehringer, but the triple-mechanism positioning targets the safety + organ-protection lane that competitors leave open.
Beijing-based Syneron Bio raised $150M in Series B funding with AstraZeneca among investors to develop macrocyclic peptide drugs. The FDA also proposed a new expedited IND pathway.
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.